Literature DB >> 3156873

T-cell subsets in multiple sclerosis: lack of correlation between helper and suppressor T cells and the clinical state.

J B Zabriskie, L Mayer, S M Fu, C Yeadon, V Cam, C Plank.   

Abstract

Peripheral blood T-lymphocyte subsets were investigated in a group of 26 multiple sclerosis (MS) patients of different clinical categories and compared to those of 15 normal controls and 7 other patients with known immunoregulatory disorders. In addition 17 well-documented acute relapses in 11 MS patients were also studied, some of whom were tested serially prior to, during, and after the acute attack. Using three different commercial preparations of monoclonal antibodies directed against human T3, T4, and T8 lymphocyte markers, none of the MS patients irrespective of disease category exhibited any changes in the absolute numbers of T-cell subsets or ratios thereof; this was true during either quiescent or active stages of the disease. In contrast, several patients with known immunoregulatory disorders exhibited clear changes in T4/T8 ratios. Factors such as type of patient studied, sampling error, and methods of isolation of mononuclear cells, as well as source of monoclonal antibody, failed to explain the lack of change in T-cell subsets in these patients. Thus, our data fail to confirm the previous reports of a decrease in the absolute numbers of T8 cells or the increase in the T4/T8 ratios in active or quiescent MS patients. These negative findings underscore the need for further studies relating these markers to meaningful functional properties of these cells and their interaction with the relevant target organs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156873     DOI: 10.1007/bf00915162

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  23 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  On the evaluation of disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1961-08       Impact factor: 9.910

3.  Isolation of lymphocytes, granulocytes and macrophages.

Authors:  A Bøyum
Journal:  Scand J Immunol       Date:  1976-06       Impact factor: 3.487

4.  Lymphocyte function and the role of regulator cells in multiple sclerosis.

Authors:  J P Antel; D P Richman; M E Medof; B G Arnason
Journal:  Neurology       Date:  1978-09       Impact factor: 9.910

5.  T gamma cells express T lymphocyte-associated antigens.

Authors:  R I Fox; L F Thompson; J R Huddlestone
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

6.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Authors:  S L Hauser; D M Dawson; J R Lehrich; M F Beal; S V Kevy; R D Propper; J A Mills; H L Weiner
Journal:  N Engl J Med       Date:  1983-01-27       Impact factor: 91.245

7.  A two-label microfluorometric analysis of the expression of OKT5 and Leu 2a antigens on peripheral blood lymphocytes in patients with multiple sclerosis.

Authors:  L F Kastrukoff; D W Paty
Journal:  J Neuroimmunol       Date:  1984-04       Impact factor: 3.478

8.  Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis.

Authors:  D Santoli; W Hall; L Kastrukoff; R P Lisak; B Perussia; G Trinchieri; H Koprowski
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

9.  Intensive immunosuppression in patients with disseminated sclerosis. III. Lymphocyte response in vitro.

Authors:  S C Knight; E M Lance; J Abbosh; A Munro; J O'Brien
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

10.  Human T cell hybridomas secreting factors for IgA-specific help, polyclonal B cell activation, and B cell proliferation.

Authors:  L Mayer; S M Fu; H G Kunkel
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

View more
  4 in total

1.  Determination of activated lymphocytes in peripheral blood of patients with multiple sclerosis.

Authors:  A D Crockard; T A McNeill; J McKirgan; S A Hawkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-01       Impact factor: 10.154

Review 2.  Pathogenesis of multiple sclerosis. A critical reappraisal.

Authors:  C M Poser
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

3.  Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis.

Authors:  S Fredrikson; P Eneroth; H Link
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

4.  Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse?

Authors:  A J Thompson; J Brazil; C A Whelan; E A Martin; M Hutchinson; C Feighery
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.